Core Biogenesis Launches Peauvita, Peauforia Recombinant Growth Factors that Combat Aging in 14 Days

beautiful Asian woman in white robe looking in mirror smiling touching face plants in background
Image by metamorworks at Adobe Stock

Biotech and plant-derived recombinant protein specialist Core Biogenesis has entered the beauty scene with two major launches to combat four key signs of aging, Peauvita (FGF-2-oleosome) and Peauforia (EGF-oleosome). Per the company, these advanced growth factors offer unprecedented stability and efficacy against wrinkles, hyperpigmentation and more.

Biotech-derived Actives for Skin Vitality, Euphoria

Using a patent-pending plant biofactory production process, Core Biogenesis produces bioactive compounds such as peptides and proteins from the seeds of Camelina sativa plants. These proteins are fused to the surface of oleosomes — natural oilseed reservoirs — to create stable actives with enhanced skin delivery.

The result yields actives such as the company's new ingredients:

  • Peauforia (FGF-2-oleosome); pending INCI: Water (Aqua) (and) Glycerin (and) Xanthan Gum (and) Camelina Sativa Oleosomes/Camelina Sativa sr-(Arabidopsis Thaliana Polypeptide-2sh-Polypeptide-1) (and) Gluconolactone; and
  • Peauvita (EGF-oleosome); pending INCI: Water (Aqua) (and) Glycerin (and) Xanthan Gum (and) Camelina Sativa Oleosomes/Camelina Sativa sr-(Arabidopsis Thaliana Polypeptide-2sh-Oligopeptide-1) (and) Gluconolactone.

The products are inspired by the French term for skin, peau, combined with the concepts of vitality and euphoria.

"Our focus has been on growth factors, essential proteins naturally found in the skin that diminish with age, contributing to the aging process,” said Alexandre Reeber, president and CEO of Core Biogenesis. “Through our innovative technology, we’ve successfully stabilized two of the most sought-after growth factors, [epidermal growth factor] (EGF) and [fibroblast growth factor 2] (FGF-2), which promise enhanced efficacy for skin care brands and, ultimately, the consumer.”

In vivo Anti-aging Efficacy in 14 Days

According to the company, Peauvita (EGF - Oleosome) and Peauforia (FGF2 - Oleosome) were rigorously tested in a placebo-controlled clinical trial (n = 60) by a third party using each active at 1%. Results revealed Peauvita significantly reduced the appearance of fine lines and wrinkles while boosting skin firmness in just 14 days.

Moreover, Peauforia diminished melanin in hyperpigmented areas and restored the skin barrier within the same timeframe. Taken together, the actives offer a comprehensive solution to target these four primary signs of aging.

"The clinical results were truly remarkable, with noticeable improvements in just 14 days,” commented Tony Abboud, head of cosmetics at Core Biogenesis. “I am confident that skin care brands worldwide will be eager to incorporate Peauvita and Peauforia into their upcoming formulations.”

More in Actives